1. Introduction {#s0005}
===============

Patients with stages 3 to 5 of chronic kidney disease (CKD) have a twofold fracture risk and higher morbidity and mortality compared to the healthy population ([@bb0035]; [@bb0075]). The mechanisms thought to increase this fracture risk involve secondary hyperparathyroidism due to reduced phosphaturia and vitamin D deficiency secondary to poor calcitriol synthesis, both of which lead to detrimental bone effects ([@bb0040]).

The 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) establishes a grade 2B recommendation in favor of testing bone mineral density (BMD) by DXA to assess osteoporotic fracture (OPF) risk in patients with CKD G3a-G5 CKD with risk factors for osteoporosis as long as the results impact treatment decisions ([@bb0120]). Even so, the usefulness of DXA, which is the gold standard for evaluating BMD in healthy individuals, is controversial in CKD patients due to a lack of large studies evaluating it for this particular population ([@bb0035]; [@bb0100]). Furthermore, CKD patients have significant rates of cortical bone loss and underlying metabolic bone disease, which are undetectable by DXA ([@bb0160]; [@bb0015]; [@bb0175]).

Our main objective was to establish the clinical performance of BMD as measured by DXA in the evaluation of fracture risk in women with CKD.

2. Methods {#s0010}
==========

We conducted an observational, retrospective cohort study from 1977 to 2020 in a National Health Institute in Mexico City. The study group included 218 female patients ≥18 years who met the following criteria: glomerular filtration rate (GFR) ≤ 60 mL/min/m^2^ and total hip and lumbar spine BMD determination by DXA. The study population was divided into two categories by age: \< 50 years and ≥ 50 years. We excluded patients with primary causes of osteoporosis including Cushing\'s syndrome, hyperthyroidism, primary hyperparathyroidism, primary hypogonadism, and central hypogonadism (i.e., Sheehan syndrome and tumors of the nervous system). Fractures and DXAs before CKD diagnosis (\< 60 mL/min/m^2^) were also excluded.

2.1. Cohort {#s0015}
-----------

The clinical charts of 830 female patients diagnosed with CKD were reviewed. Among these, 218 patients met the inclusion criteria. All DXAs after CKD diagnosis were documented, resulting in a total of 314 BMD records. For statistical purposes, in non-fractured patients the last DXA was taken into consideration, whereas for fractured patients the DXA closest to the fracture was used.

2.2. Chronic kidney disease {#s0020}
---------------------------

The first patient with CKD was recorded in 1977, the year of CKD diagnosis was collected directly from the clinical records and verified using the KDIGO 2012 definition for kidney failure (GFR \< 60 mL/min/m2 for \>3 months) ([@bb0125]). GFR was calculated using the CKD-EPI formula ([@bb0135]). Patients were classified using the KDIGO staging system: G3a (45--59 mL/min/m^2^), G3b (30--44 mL/min/m^2^), G4 (15--29 mL/min/m^2^), and G5 (\< 15 mL/min/m^2^).

2.3. Dual-energy x-ray absorptiometry {#s0025}
-------------------------------------

The first DXA after CKD diagnosis was recorded in November 1998, and the last one in January 2020. Total hip and lumbar spine BMD determinations were measured using a Hologic QDR 1000 W DXA instrument (Hologic Inc., Waltham, MA, USA) with precisions (CV %) of 0.9% (L1--L4 spine) and 1.2% (hip). The BMD results were expressed in T-score and g/cm^2^ and classified according to WHO parameters as normal (−1.0 or above), osteopenia (between −1.0 and −2.5), and osteoporosis (−2.5 or below) ([@bb0210]). A T-score \< −1.0 indicated an abnormal bone diagnosis.

2.4. Clinical and biochemical parameters {#s0030}
----------------------------------------

The clinical parameters included age, year of CKD onset, anthropometry (weight, height, and body mass index \[BMI\]), BMD by DXA (BMD and T-scores for hip and lumbar spine), renal transplant status, current treatment regimens for osteoporosis (i.e., bisphosphonates, denosumab, teriparatide), immunosuppressive treatment (i.e., corticosteroids, post-transplant immunosuppression), and calcium and vitamin D supplementation. The biochemical parameters included serum intact parathyroid hormone (PTH), total serum calcium, phosphate, vitamin D (25 \[OH\] D3), creatinine, and albumin. PTH and 25 (OH) D3 were registered within ±12 months, whereas other biochemical parameters were assessed within ±3 months of the analyzed DXA.

Calcium correction was performed using the following formula: serum total calcium (mg/dL) + 0.8 × \[4.0 − serum albumin (g/dL)\] ([@bb0165]). Patients were classified into three groups according to their 25 (OH) D3 levels: deficiency (\< 20 ng/mL), insufficiency (20--29 ng/mL), and normal (≥ 30 ng/mL) ([@bb0170]).

2.5. Parathyroid hormone levels {#s0035}
-------------------------------

PTH levels were evaluated using the standard values established by the institutional laboratory. PTH levels were considered normal if they were \< 88 ng/L and high if they were ≥ 88 ng/L. PTH levels were also divided into quartiles (Q) of the following values for operational purposes: Q1: 4.7 ng/L--59 ng/L; Q2: 59.3 ng/L--123.9 ng/L; Q3: 129.2 ng/L--294.8 ng/L; Q4: 309.7 ng/L--2535 ng/L.

2.6. Fractures {#s0040}
--------------

The WHO defines OPFs, including asymptomatic vertebral fractures, as those that occur in adults after minimal trauma, such as a fall from standing height or less ([@bb0200]). All OPFs were registered from the clinical records and radiographic files throughout the study period. We collected data from radiography, computed tomography scan, and magnetic resonance imaging reports. All fractures were diagnosed by expert radiologists. The patients were classified according to fracture type: proximal femur (hip), vertebrae (lumbar spine), distal radius (wrist), or other fragility fractures (FF) (i.e., ankle, tibia, humerus). We excluded fractures caused by severe trauma (i.e., high-speed motor vehicle collision, injury from a projectile) and those related to malignancy.

2.7. Body mass index {#s0045}
--------------------

We used BMI as a metric parameter for establishing anthropometry characteristics regarding the percentage of total body fat. Each patient was classified into one of three BMI categories: underweight (\< 18.5 kg/m^2^), normal weight (≥ 18.5 and \< 25 kg/m^2^), and overweight or obesity (≥ 25 kg/m^2^) ([@bb0205]).

3. Statistical analysis {#s0050}
=======================

Results were expressed in mean and standard deviation. Variables without a normal distribution were expressed as proportion, median and interquartile range. Variables used to compare the fractured group and the non-fractured group were evaluated using the following: Pearson\'s chi squared test for qualitative variables, Student\'s *t*-test or Mann-Whitney *U* test for quantitative variables, Kruskal-Wallis for comparing groups, and Pearson\'s rho for correlation analysis between two quantitative variables. According to the fracture event we made a binary logistic regression. Univariate and multivariate models were adjusted for significant variables for lumbar spine and total hip T-score. *P* values \< 0.05 were considered statistically significant. Kaplan-Meier survival analyses were conducted for fracture events for total hip and lumbar spine values associated with other variables. Receiver operating characteristic (ROC) analysis was made to estimate the area under curve (AUC), sensitivity, specificity, and cutoff values for total hip and lumbar spine T-score, and biochemical parameters; the reported cutoff values were the highest in terms of average sensitivity and specificity. Data was processed using Microsoft Office Excel 365 (Redmond, Washington, USA) and STATA/SE 14.0.

4. Results {#s0055}
==========

During the study period, 218 women with CKD were evaluated (non-fractured = 170, fractured = 48). The median age was 60 years (40--73 IQ range). The CKD evolution median time was 12 years (7--18 IQ range), and CKD evolution time at the moment of the first DXA on record was 5 years (2--10 IQ range). The mean GFR was 29.63 mL/min/m2 (±17.44). No CKD stage (G3a--G5) predominated between fractured and non-fractured groups (*p* = 0.131). In the total group the average of DXAs performed was 1.3 per patient. Forty-eight women (28.23%) presented OPF, of which 12.5% had more than one fracture, most in the lumbar spine (36.3%, *n* = 20), whereas the others were in the hip (32.7%, *n* = 18), FF (23.6%, *n* = 13), and wrist (7.27%, *n* = 4).

Women in the fractured group were older than those in the non-fractured group (57 vs. 69 years, *p* = 0.0072) and had a lower BMD with osteoporosis more frequently found in the lumbar spine (52 vs. 25%, *p =* 0.000) and in the hip (46 vs. 13%, *p =* 0.000) ([Table 1](#t0005){ref-type="table"}).Table 1Baseline characteristics of the 218 patients[§](#tf0005){ref-type="table-fn"}.Table 1**No fractures (*****n***** = 170)Fractures (*****n***** = 48)*****P*****ValueGeneral characteristics**Age (years)57 (37--70)69 (51--75)**0.0072**[†](#tf0010){ref-type="table-fn"}CKD evolution (years)12 (7--18)11 (7.5--16)0.56[†](#tf0010){ref-type="table-fn"}CKD to first DXA (years)4 (1--9)5 (2--8.5)0.29[†](#tf0010){ref-type="table-fn"}BMI (Kg/m^2^)26.4 (±6.37)26.1 (±4.57)0.27Lumbar spine BMD (g/cm^2^)0.872 (±0.151)0.767 (±0.151)**\<0.000**[⁎](#tf0030){ref-type="table-fn"}Lumbar spine T-score−1.57 (±1.37)−2.51 (±1.39)**\<0.000**[⁎](#tf0030){ref-type="table-fn"}Total hip BMD (g/cm^2^)0.784 (±0.151)0.674 (±0.160)**\<0.000**[⁎](#tf0030){ref-type="table-fn"}Total hip T-score−1.27 (±1.11)−2.13 (±1.18)**\<0.000**[⁎](#tf0030){ref-type="table-fn"}[a](#tf0020){ref-type="table-fn"}**Lumbar spine diagnosis** *Normal*53 (31.1)5 (10.4) *Osteopenia*75 (44.1)18 (37.5) *Osteoporosis*42 (24.7)25 (52.1)**\<0.000**[⁎](#tf0030){ref-type="table-fn"}[a](#tf0020){ref-type="table-fn"}**Total hip diagnosis** *Normal*72 (42.3)10 (20.8) *Osteopenia*76 (44.7)16 (33.3) *Osteoporosis*22 (12.9)22 (45.8)**\<0.000**[⁎](#tf0030){ref-type="table-fn"}**Fracture events**NS[‡](#tf0015){ref-type="table-fn"} *Lumbar spine*--20 (36.3) *Femur*--18 (32.7) *Radius*--4 (7.27) *FF*[b](#tf0025){ref-type="table-fn"}--13 (23.6)**CKD stage** *3a*51 (30)7 (14.5) *3b*42 (24.7)11 (22.9) *4*37 (21.7)15 (31.2) *5*40 (23.5)15 (31.2)0.12  **Laboratory values**GFR mL/min/m^2^30.6 (±17.6)25.92 (±16.4)0.09PTH pg/mL, *n* = 126140.2 (62.7--341.4)139.2 (71.9--322.7)0.52[†](#tf0010){ref-type="table-fn"}Serum calcium mg/dL, *n* = 1899.32 (±0.79)9.33 (±0.75)0.99Corrected calcium mg/dL, *n* = 1779.48 (±0.67)9.45 (±0.67)0.83Serum phosphate mg/dL, *n* = 1844.04 (±1.11)4.05 (±1.15)0.9525 (OH) D3 ng/mL, *n* = 9520.4 (±10.3)17.2 (±9.02)0.17Albumin g/dL, *n* = 1913.86 (±0.65)3.85 (±0.56)0.96  **Comorbidities**Type 2 Diabetes70 (41.1)26 (54.1)0.10Systemic lupus erythematosus28 (16.4)7 (14.5)0.75Hypothyroidism46 (27)17 (35.4)0.25Renal transplant51 (30)8 (16.6)0.06Calcium treatment70 (41.1)26 (54.1)0.14Vitamin D treatment72 (42.3)25 (52)0.11Osteoporosis treatment12 (7)8 (16.6)0.61Immunosuppressive treatment64 (37.6)10 (20.8)**0.03**[⁎](#tf0030){ref-type="table-fn"}[^1][^2][^3][^4][^5][^6]

No differences were observed between the groups in terms of weight, CKD evolution time, systemic lupus erythematosus, type 2 diabetes (T2D), primary hypothyroidism, kidney transplant history, GFR, PTH levels, corrected calcium, P, 25 (OH) D3, and albumin. There was no significant difference in fracture incidence among patients who received calcium or 25 (OH) D3 supplementation or those under osteoporosis. However, we found an association between immunosuppressive treatment and a lower fracture incidence (*p* = 0.03) ([Table 1](#t0005){ref-type="table"}).

Regarding CKD evolution time and fracture onset, lumbar spine fractures developed earlier when compared to hip fractures (5.25 years vs. 9.42 years, *p =* 0.0174). It is worth mentioning that no association was found between BMD, BMI or biochemical parameters with fracture incidence in any specific site.

BMI had a significant positive correlation with total hip and lumbar spine BMD (*p =* 0.0000, *p =* 0.0000), whereas age (*p =* 0.013) had a negative correlation with hip BMD, and PTH (*p =* 0.0046, *p =* 0.008) had a negative correlation with hip and lumbar spine BMD ([Table 2](#t0010){ref-type="table"}). However, there were no significant differences between fracture incidences when compared with BMI classification, age (\< 50 and ≥ 50 years), and PTH.**Table 2**Correlations between lumbar spine and total hip BMD with other variables.Table 2**Lumbar spine BMD (*****r*****)*****P*****ValueTotal hip BMD (*****r*****)*****P*****Value**Age−0.0880.192−0.166**0.013**Weight0.381**\<0.000**0.429**\<0.000**Height0.147**0.029**0.1110.10BMI0.337**\<0.000**0.402**\<0.000**Years with CKD0.0340.61−0.0130.84Lumbar spine BMD----0.686**\<0.000**Total hip BMD0.686**\<0.000**----GFR−0.0140.830.0780.24PTH−0.167**0.046**−0.236**0.008**Corrected calcium0.1030.170.1070.15Serum phosphate0.0930.200.0220.7525 (OH) D30.0910.370.1520.14[^7]

In the univariate analysis of fractures, we found that age (*p* = 0.043), hip and lumbar spine T-scores (*p* = 0.000, p = 0.000), G4 (*p* = 0.032) and G5 stages (*p* = 0.046) were statistically significant, whereas only hip and lumbar spine T-scores (p =0.000, *p* =0.002) remained significant in the multivariate analysis. For each standard deviation decrease in T-score, the risk of hip and lumbar spine fracture increased by 2.7 (95% CI 1.56 to 4.76, p = 0.000) and 2.04 times (95% CI 1.29 to 3.12, p = 0.002) ([Table 3](#t0015){ref-type="table"}).**Table 3**Odds ratios according to binary logistic regression by fracture for univariate and multivariate analysisTable 3**Univariate95% IC*****P*****ValueSpineTotal HipMultivariate**[a](#tf0035){ref-type="table-fn"}**95% CI*****P*****ValueMultivariate**[b](#tf0040){ref-type="table-fn"}**95% CI*****P*****Value**Age1.011.00--1.03**0.043**1.020.98--1.050.211.010.98--1.040.38Weight0.990.97--1.010.661.020.98--1.000.211.040.99--1.000.06Height0.150.00--9.590.370.370.00--4250.780.300.00--3670.74Years with CKD0.980.94--1.030.561.040.96--1.130.251.020.93--1.110.62Lumbar spine T-Score0.590.45--0.77**0.000**0.490.32--0.77**0.002**------Total hip\
T-Score0.510.38--0.70**0.000**------0.370.21--0.64**0.000**G3b1.900.67--5.350.225.090.34--75.60.233.850.25--58.40.33G42.951.09--7.96**0.032**9.510.76--1180.0811.30.88--1460.06G52.731.01--7.33**0.046**10.50.81--1360.0710.40.78--1390.07PTH1.000.99--1.000.521.000.99--1.000.960.990.99--1.000.90Corrected calcium0.940.56--1.590.831.070.76--3.950.182.420.94--6.240.06Serum phosphate1.000.73--1.380.950.850.52--1.390.520.790.48--1.310.38Albumin0.980.58--1.660.961.030.54--3.110.551.290.50--3.350.59[^8][^9][^10]

More than 50% of fractures took place during the first ten years of follow-up. With lower GFR (\< 30 mL/min/m^2^), fracture events occurred earlier when compared to higher GFR (≥ 30 mL/min/m^2^) ([Fig. 1](#f0005){ref-type="fig"}). Comorbidities, such as T2D and hypothyroidism, accelerated fracture onset, whereas renal transplant delayed it ([Fig. 2](#f0010){ref-type="fig"}).Fig. 1Fracture survival rate among women with CKD(A) Stratified by hip and lumbar spine fracture (B) Hip fracture stratified by osteoporosis and no osteoporosis (normal and osteopenia) BMD by DXA (C) Lumbar spine stratified by osteoporosis and no osteoporosis (normal and osteopenia) BMD by DXA (D) Stratified by the KDIGO G3a and G3b (GFR \> 30 mL/min); G4 and G5 (GFR \<30 mL/min).Fig. 1Fig. 2Fracture survival rate among women with CKD and comorbidities.(A) Lumbar spine fracture stratified by the KDIGO G3a and G3b (GFR \> 30 mL/min); G4 and G5 (GFR \> 30 mL/min), diagnosis of osteoporosis and no osteoporosis (normal and osteopenia) by DXA (B) Hip fracture stratified by the KDIGO G3a and G3b (GFR \> 30 mL/min); G4 and G5 (GFR \> 30 mL/min), diagnosis of osteoporosis and no osteoporosis (normal and osteopenia) BMD by DXA (C) Stratified by transplant and no transplant (D) Stratified by T2D and no T2D.Fig. 2

The ROC analysis for fracture incidence demonstrated that the AUC was larger with the total hip (0.7098, *p =* 0.000) and lumbar spine T-score (0.6916, *p =* 0.000). Biochemical parameters did not show any predictive value for the fracture event. ([Fig. 3](#f0015){ref-type="fig"} and [Table 4](#t0020){ref-type="table"}).Fig. 3ROC analysis on the prediction for any type of fracture for total hip and lumbar spine T-score.Fig. 3Table 4ROC analysis on bone mineral densities for fracture.Table 4**AUCCutoff value*****P*****ValueSensitivitySpecificityT-score**[⁎](#tf0115){ref-type="table-fn"}Lumbar spine≤ − 132.3589.58≤ −1.754.7166.67**0.6916**≤ −2.5**\<0.000**78.2450≤ −2.783.5350≤ −2.988.8239.58Total hip**0.7098**≤ − 1**\<0.000**42.9479.17≤ −1.77066.67≤ −2.587.6539.58≤ −2.789.4127.08≤ −2.991.1820.83[^11][^12]

5. Discussion {#s0060}
=============

We found that total hip and lumbar spine BMD as measured by DXA is a useful tool for predicting fractures in female patients with CKD independently of age or CKD stage. Our data show that there is a statistically significant correlation between total hip and lumbar spine BMD (*r* = 0.68, p = 0.000), which suggests that both measurements are equally useful in predicting fracture risk. Supporting our findings, a meta-analysis by Bucur et al. found that BMD predicts fracture risk in CKD patients regardless of the measuring site ([@bb0035]). This suggests that the pathophysiology of CKD bone disorders is complex and does not depend solely on PTH levels ([@bb0175]; [@bb0185]). Despite this, hip BMD is recognized as the best fracture predictor among CKD patients ([@bb0105]; [@bb0080]; [@bb0215]) due to the PTH predominantly exercising its effect on cortical bone, which is the main form in the hip whereas the lumbar spine is formed mostly by trabecular bone ([@bb0215]; [@bb0065]; [@bb0060]; [@bb0045]). We did not find a significant correlation between total hip and lumbar spine BMD with PTH levels (*r* = −0.23, *p* = 0.008) ([Table 2](#t0010){ref-type="table"}).

Our cohort contained 48 fractures, of which 38 (79%) occurred in women age 50 or older. Of these, 92% were found in women with an abnormal bone diagnosis (osteopenia or osteoporosis). However, we found that even though only 20% of fractures occurred in women younger than 50 years, 90% of these were also found in women with an abnormal bone diagnosis, meaning that BMD is a useful fracture risk prediction tool independently of age for this particular population. This finding is supported by the fact that age was not significant in the multivariate model analysis ([Table 3](#t0015){ref-type="table"}).

We found no relationship between fracture risk and CKD stage, as seen in previous studies. However, when we followed each CKD stage separately, G4 and G5 presented fracture events earlier ([Fig. 1](#f0005){ref-type="fig"}). Even though advanced CKD (G4, G5) increased the fracture risk by 2.95 and 2.73 times in the univariate analysis, respectively. In the multivariate analysis, only BMD remained significant. This finding reflects that BMD measurement is the most important parameter for predicting fracture risk in these patients ([Table 3](#t0015){ref-type="table"}).

According to S. L. West and the National Kidney Foundation, in patients with CKD stages 1 to 4, the primary cause of fractures is osteoporosis ([@bb0040]; [@bb0190]). However, stage 5 patients have many mineral metabolism disturbances, resulting in a more challenging diagnosis. Therefore, the KDIGO guidelines suggest that it is reasonable to perform a bone biopsy on these patients to guide treatment course ([@bb0120]). In our Kaplan-Meier analysis, we found that fracture events occurred earlier in patients with osteoporosis. Half of them reached fracture events at approximately fifteen years, whereas only 25% of non-osteoporotic patients experienced a fracture during follow-up ([Fig. 1](#f0005){ref-type="fig"}). Even when following patients with advanced kidney failure (GFR \< 30 mL/min/m^2^) and osteoporosis, the latter was the main factor fracture determinant over time ([Fig. 2](#f0010){ref-type="fig"}).

In the general population with osteoporosis, the most common fractures occur in the lumbar spine (500,000 symptomatic fractures and more than one million subclinical fractures yearly in the United States), followed by hip fractures (300,000 yearly) ([@bb0145]). There is a significantly increased risk of hip fracture in patients with CKD ([@bb0115]). A GFR ≤ 60 mL/min/m^2^ confers a twofold risk for this event (OR 2.12) ([@bb0160]). However, the frequency of vertebral fractures is similar to that in the general population ([@bb0070]). This phenomenon is explained by the PTH mechanism. Both statements agree with our findings, in which we observed a major incidence of lumbar spine fractures (36.5%) but a similar incidence of total hip fractures (32.7%). Nevertheless, most of the vertebral fractures that we reported were incidental findings in the radiologic files, which could be explained because of their subclinical presentation. On the other hand, 250,000 fractures at other sites occur yearly in the general population with osteoporosis ([@bb0145]). In our study, there was an important proportion of FF (23.6%) in which age, GFR, and biomarkers were similar, reinforcing BMD as the main predictive risk factor for overall fractures.

Interestingly, in kidney transplant patients, fractures occurred later than the average fracture onset, which suggests that the recovery of renal function delays OPF events. The latter is supported by the fact that we also observed that the use of immunosuppressors was associated with a lower fracture incidence. According to Ball et al., transplanted patients initially have a 34% higher fracture risk than dialyzed patients; however, after the first 630 postoperative days, this relationship reverts ([@bb0020]; [@bb0155]). Iyer et al. demonstrated that during the first year after transplant, central BMD remains the same or even increases, whereas peripheral BMD decreases ([@bb0095]). Based on these results, we found that transplanted patients had a higher incidence of FF and wrist fractures than did non-transplanted patients.

According to Guowei Li et al., T2D patients have a propensity for OPF with higher BMD values ([@bb0095]; [@bb0140]). In fact, menopausal women with T2D, experienced more fractures compared to individuals without diabetes, especially in the hip ([@bb0055]; [@bb0110]; [@bb0030]; [@bb0130]). Hyperinsulinism has a trophic effect on bone initially; however, this bone matrix deteriorates due to advanced glycation end products, resulting in an overall defective bone ([@bb0090]; [@bb0050]; [@bb0010]). In support of this statement, we found that 54% of patients in the fractured group had T2D, and these patients presented fractures earlier than non-diabetic patients ([Fig. 2](#f0010){ref-type="fig"}D).

The WHO\'s osteoporosis guidelines estimate that the risk of fracture increases for each standard deviation decrease in BMD, peaking at −2.5 SD ([@bb0200]). We consider evaluating BMD using DXA in women with CKD appropriate because the AUC obtained was 0.70 for total hip and 0.69 for lumbar spine, with good sensitivity (88% and 78%, respectively) and specificity (40% and 50%, respectively) for a cutoff T-score value of ≤ −2.5 SD. Iimori et al. reported similar performance in the evaluation of total hip and lumbar spine T-scores for fracture prediction in women with CKD with an AUC of 0.74 and 0.67, respectively, and a cutoff value of \< −2.7 SD in total hip with 80% sensitivity and 63.8% specificity ([@bb0105]).

It is worth mentioning that only 43.73% of the patients who experienced a fracture received treatment for osteoporosis; as evidenced by Andrade et al. who found that only 24% of postmenopausal women received therapy during the year following a fracture ([@bb0005]). According to Weycker et al. and the International Osteoporosis Foundation, about 50% of women who started osteoporosis therapy abandoned it within 12 months due to side effects and lack of information ([@bb0195]; [@bb0085]). Osteoporosis treatment reduces risk of vertebral fracture by 77% and risk of non-vertebral fracture by 49%; it also decreases mortality by up to 10% in older and fragile patients ([@bb0025]). This is especially true in patients with CKD, for whom therapeutic adherence becomes even more complicated because primary pharmacological treatments for osteoporosis, such as bisphosphonates, are contraindicated in advanced renal failure ([@bb0135]; [@bb0145]). However, patients with CKD have many comorbidities that represent excessive costs and make osteoporosis treatment less important from the perspective of patients and sometimes that of medical staff ([@bb0120]; [@bb0150]).

6. Conclusions {#s0065}
==============

BMD measured by DXA is a useful fracture prediction tool for women with CKD independently of age, as it has a sensitivity and specificity similar to that of the general population. It appears to be appropriate for the diagnosis, follow-up, and treatment of patients with renal failure. In addition, it might eliminate the need for a bone biopsy in advanced cases. Unfortunately it is poorly used, as we found in our study the average of DXAs was 1.3 despite the long CKD evolution.

CKD stage alone correlates poorly with an increased fracture risk; however, the combination of advanced renal failure and osteoporosis results in earlier fracture events. Although PTH clearly plays a key role in the physiopathology of bone disease, it does not seem to be a strong fracture predictor and therefore should not be used alone. Given that patients with T2D present fractures earlier, they should be followed closely. Finally, kidney transplant may delay fractures events, but prospective studies are needed ([@bb0180]).

7. Limitations {#s0070}
==============

Given the fact that this was a retrospective study, some data regarding patient records are lacking. For instance, total and bone-specific alkaline phosphatase were inconsistently measured and thus not taken into account for statistical analyses. Furthermore, tobacco and alcohol use were seldom reported and therefore we were unable to calculate the FRAX score.

Ethical standards {#s0075}
=================

The present study has been approved by the ethics committee and has been performed in accordance with the ethical standards. All patients gave their informed consent prior to their inclusion in the study.

CRediT authorship contribution statement {#s0080}
========================================

**Valeria E. Gómez-Islas:** Conceptualization, Methodology, Formal analysis, Investigation, Data curation, Writing - original draft, Writing - review & editing, Visualization. **Kevin R. García-Fong:** Conceptualization, Methodology, Formal analysis, Investigation, Data curation, Writing - original draft, Writing - review & editing, Visualization. **Rosa E. Aguilar-Fuentes:** Data curation, Methodology, Investigation, Writing - review & editing. **Salvador Hernández-Castellanos:** Data curation, Investigation, Methodology, Writing - review & editing. **Alfredo Pherez-Farah:** Data curation, Investigation, Writing - original draft, Writing - review & editing. **Sofía A. Méndez-Bribiesca:** Investigation, Writing - original draft, Writing - review & editing. **Juan M. López-Navarro:** Conceptualization, Data curation. **Hillary K. Osorio-Landa:** Conceptualization, Data curation. **Sergio L. Carbajal-Morelos:** Conceptualization, Data curation. **Areli M. Zúñiga-Guzmán:** Data curation. **Iván Pérez-Díaz:** Conceptualization, Supervision, Validation, Project administration, Methodology, Formal analysis, Writing - review & editing.

Declaration of competing interest
=================================

The authors state that we have read and agree to abide by the *Bone Reports* conflict of interest policy. Hereby, we acknowledge that we do not have any conflict of interest that could be perceived as prejudicing the impartiality of the research reported. Furthermore, we understand that we are obliged to promptly reveal any changes in our interests, affiliations or activities which may give rise to a conflict of interest and in such case the conflict of interest statement will be updated.

[^1]: Data are given as the mean ± SD or percentage.

[^2]: Data are given as median and range.

[^3]: Any statistical difference between fracture site.

[^4]: T-score diagnosis based on the WHO standards.

[^5]: Fragility fractures as defined by WHO guidelines.

[^6]: Statistical significance (*p* \< 0.05).

[^7]: Bold numbers show statistical significance (*p* \< 0.05).

[^8]: Bold numbers show statistical significance (*p* \< 0.05).

[^9]: Adjusted by age, weight, height, years with CKD, lumbar spine T-Score, GFR, PTH, corrected calcium, phosphorus and albumin.

[^10]: Adjusted by age, weight, height, years with CKD, total hip T-Score, GFR, PTH, corrected calcium, phosphorus and albumin.

[^11]: Bold numbers show statistical significance (p \< 0.05).

[^12]: BMD cutoff values, sensitivity and specificity were equivalent
